Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Jean-Luc Van Laethem, ESMO 2021: Updated Results of the Phase II KEYNOTE-224 Study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 5th 2021

touchONCOLOGY joins Professor Jean-Luc Van Laethem (Erasme University Hospital, Brussels, Belgium), principle investigator of the KEYNOTE-224 study, to discuss the updated results for pembrolizumab monotherapy as first-line therapy for advanced hepatocellular carcinoma.

Questions
1. What were the objectives of the KEYNOTE-224 study? (00:38-01:33)
2. What have previous study findings taught us about the clinical utility of pembrolizumab monotherapy as therapy for advanced hepatocellular carcinoma (HCC)? (01:33-02:52)
3. Could you give us an overview of the latest results from the KEYNOTE-244 study? (02:52-04:00)
4. Where do you place pembrolizumab in future treatment paradigms for HCC? (04:00-05:12)
5. How can outcomes with pembrolizumab in this indication be further improved and what future studies are planned? (05:12-06:03)

Disclosures: Jean-Luc Van Laethem has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ESMO 2021 Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup